Scholar Rock Shares Plunge Despite Sarepta Gene Therapy Approval
May 27, 2023
Trending News ☀️
Scholar Rock Holding ($NASDAQ:SRRK) Corp. (SCHR) is a biotechnology company focused on developing therapeutics targeting the activation of latent proteins. Despite the recent approval of Sarepta Therapeutics’ gene therapy, Scholar Rock has continued its slide in the markets, with shares tumbling on Tuesday. The company is scheduled to report their quarterly earnings on August 8th.
Price History
On Thursday, SCHOLAR ROCK HOLDING experienced a downturn in its stock price, with shares dropping by 8.5% from the previous closing price of $6.9. The poor performance of the shares demonstrates that investors may have been unfazed by the news, giving the company a weak start to the day. However, investors remain hopeful that Scholar Rock Holding will be able to capitalize on the potential of the Sarepta gene therapy and its own pipeline of products in order to bolster its stock price in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for SRRK. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -165.93 | -405.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for SRRK. More…
| Operations | Investing | Financing |
| -133.18 | -11.14 | 195.43 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for SRRK. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 314.72 | 86.07 | 4.4 |
Key Ratios Snapshot
Some of the financial key ratios for SRRK are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 17.4% | – | -404.8% |
| FCF Margin | ROE | ROA |
| -403.0% | -42.9% | -33.4% |
Analysis
As GoodWhale, we have analyzed the financials of SCHOLAR ROCK HOLDING and found that the company is strong in asset, but weak in dividend, growth, and profitability. Our Star Chart shows a health score of 4/10 with regard to its cashflows and debt, which indicates that the company might be able to sustain its future operations even in times of crisis. Based on our analysis, we classify SCHOLAR ROCK HOLDING as an ‘elephant’, a type of company that has a lot of assets after deducting off liabilities. Investors who are interested in investing in companies with stable performance and strong asset may be interested in SCHOLAR ROCK HOLDING. More…
Peers
The competition in the biopharmaceutical industry is becoming increasingly fierce as companies race to develop new and innovative treatments.
– NLS Pharmaceutics Ltd ($NASDAQ:NLSP)
NLS Pharma is a specialty pharmaceutical company that focuses on the development and commercialization of innovative drugs for the treatment of serious and life-threatening diseases. The company’s products are available in more than 60 countries worldwide. NLS Pharma has a market cap of 14.16M as of 2022 and a Return on Equity of 570.66%. The company’s products are used to treat a variety of serious and life-threatening diseases, including cancer, HIV/AIDS, and organ transplantation.
– Vaxart Inc ($NASDAQ:VXRT)
Vaxart Inc. is a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its vaccine candidates include flu, norovirus, respiratory syncytial virus, and hepatitis B. The company was founded by Andrew J. Radin and Wouter Latour on October 4, 2013 and is headquartered in South San Francisco, CA.
– Nascent Biotech Inc ($OTCPK:NBIO)
Nascent Biotech Inc is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics for the treatment of cancer and autoimmune diseases. The company’s market cap as of 2022 is $18.73M and its ROE is 55.87%. Nascent Biotech Inc is headquartered in San Diego, California.
Summary
Scholar Rock Holding (SRRK) has experienced a decline in its stock price in the wake of concerns regarding the approval of Sarepta Therapeutics’ gene therapy. Investors are uncertain over the potential implications of this decision, as it may indicate a shift away from SRRK’s larger mission of treating muscle diseases. With the current market uncertainty, investors should weigh the potential risks and rewards associated with this stock carefully before deciding whether or not it is a good fit for their portfolios. The company has a wide range of potential treatments for muscle diseases in development, so there is potential upside if these therapies are successful.
However, investors should also remain cautious and assess the risks associated with this stock before investing.
Related Posts
Recent Posts
